水稻生物技术发射台欢迎Carolyn Ng加入外部顾问委员会-动脉网

Rice Biotech Launch Pad welcomes Carolyn Ng to external advisory board

CISION 等信源发布 2025-07-31 19:00



可切换为仅中文







HOUSTON

休斯顿

，

July 31, 2025

2025年7月31日

/PRNewswire/ -- The

/PRNewswire/ --

Rice Biotech Launch Pad

水稻生物技术发射台

, a

，一个

Houston

休斯顿

-based accelerator focused on expediting the translation of

基于加速器，专注于加快翻译

Rice University's

莱斯大学的

health and medical technology discoveries into cures, announced today the appointment of

健康和医疗技术发现转化为治疗手段，今天宣布任命

Carolyn Ng

to its external advisory board. A current business unit partner at TPG Life Sciences Innovations, Ng brings expertise in biotech and company building with a track record of guiding early to midstage companies across a wide range of therapeutic areas.

加入其外部顾问委员会。现任TPG生命科学创新基金业务部门合伙人的吴女士在生物技术和企业建设方面具有专长，曾指导过涵盖广泛治疗领域的早期至中期公司。

'Carolyn's deep understanding of translational science, combined with her passion for fostering high-impact ventures, makes her an ideal addition to the board,' said

“卡罗琳对转化科学的深刻理解，加上她对推动高影响力企业的热情，使她成为董事会的理想人选，”

Omid Veiseh

奥米德·维赛

, professor of bioengineering at

生物工程学教授

Rice

大米

and faculty director of the Launch Pad. 'She shares our commitment to transforming early cutting-edge research into breakthrough therapies that address real-world medical challenges.'

Launch Pad的教职主任表示：“她与我们一样，致力于将早期的前沿研究转化为解决现实医疗挑战的突破性疗法。”

'Carolyn brings exceptional insight into the strategic and operational needs of growing biotech companies such as the ones we are aiming to form at the Launch Pad,' said

“卡罗琳对成长中的生物技术公司的战略和运营需求有着非凡的洞察力，正如我们希望在启动平台成立的公司一样，”

Paul Wotton

保罗·沃顿

，

executive director of the Launch Pad. 'Her global perspective on life sciences innovation will be invaluable as we continue to grow.'

Launch Pad的执行董事表示：“她在生命科学创新方面的全球视野将是无价之宝，有助于我们的持续成长。”

'As Houston rapidly emerges as a leading biotech hub, the groundbreaking research conducted at

“随着休斯顿迅速崛起为领先的生物技术中心，在这里进行的开创性研究

Rice University

莱斯大学

will be a key driver of its long-term success,' Ng said. 'The Launch Pad's unique approach, rooted in academic excellence and entrepreneurial focus, will be fundamental in transforming that research into successful therapies. I look forward to contributing my knowledge and experience to support the Launch Pad's continued growth and its mission to advance innovative therapies from lab to market.'.

“将是其长期成功的关键驱动力，”吴说。“ Launch Pad 独特的方法，植根于学术卓越和创业聚焦，将对把研究转化为成功的疗法起到根本性作用。我期待贡献我的知识和经验，支持 Launch Pad 的持续发展及其将创新疗法从实验室推向市场的使命。”

In her current position at TPG Life Sciences Innovations in

她在TPG生命科学创新部门的现任职位上

San Francisco

旧金山

, Ng leads investments into transformative early and midstage biotech companies across various therapeutic areas. She currently serves on the board of directors of Mbrace Therapeutics, Adcendo Aps and Bicara Therapeutics (NASDAQ:

，吴领导对各个治疗领域的变革性早期和中期生物技术公司的投资。她目前在Mbrace Therapeutics、Adcendo Aps和Bicara Therapeutics（纳斯达克：）的董事会任职。

BCAX

), and her previous board roles include companies such as Bicycle Therapeutics PLC (NASDAQ:

），她之前担任董事的公司包括 Bicycle Therapeutics PLC（纳斯达克：

BCYC

), Obsidian Therapeutics, Boundless Bio (NASDAQ:

），Obsidian Therapeutics，Boundless Bio（纳斯达克：

BOLD

加粗

), Epirium Bio and Visterra (acquired by Otsuka Pharmaceutical). Prior to joining TPG in 2021, Ng was a managing director at Vertex Ventures HC, where she co-led the investment team. Besides serving on the board of directors of BIOCOM California, an organization representing

)，Epirium Bio 和 Visterra（被大冢制药收购）。在2021年加入TPG之前，Ng是Vertex Ventures HC的董事总经理，她在那里共同领导了投资团队。除了担任BIOCOM California的董事会成员外，该组织代表了

California's

加利福尼亚的

life science industry, Ng is also a reviewer on the Singapore Therapeutics Development Review Panel and was recognized in 2020 by Endpoints News as one of the '20 under 40' Next Generation of Biopharma Leaders. She obtained a doctorate in cancer molecular biology from the

生命科学行业，Ng 还是新加坡治疗发展审查小组的评审员，并于2020年被Endpoints News评为“40岁以下20位”下一代生物制药领导者之一。她获得了癌症分子生物学博士学位。

National University of Singapore

新加坡国立大学

, where she was also awarded the prestigious NGS Integrative Sciences and Technology PhD scholarship.

，她还荣获了享有盛誉的NGS综合科学与技术博士奖学金。

Ng is the 16th member of the Launch Pad's external advisory board. The other members are

吴是发射台外部顾问委员会的第16位成员。其他成员是

David Allison

大卫·艾莉森

, managing director at Westlake BioPartners;

西湖生物医药合伙人管理总监；

Jason Bock

杰森·博克

, founder and CEO of CTMC;

CTMC创始人兼首席执行官；

Albert Cha

阿尔伯特·查

, managing partner of Frazier Life Sciences;

，Frazier生命科学公司的管理合伙人；

Rima Chakrabarti

里玛·查克拉巴蒂

, partner at KdT Ventures and CEO of Sentinel BioTherapeutics;

，KdT Ventures合伙人兼Sentinel BioTherapeutics首席执行官；

John Flavin

约翰·弗拉文

, founder and CEO of Portal Innovations, co-founder and chairman of Pyxis Oncology and entrepreneurial adviser of Argonne National Laboratory;

Portal Innovations的创始人兼首席执行官，Pyxis Oncology的联合创始人兼董事长，以及阿贡国家实验室的创业顾问；

Pierre Jacquet

皮埃尔·雅克

, managing director and vice chairman of L.E.K.'s health care consulting practice;

，L.E.K.医疗保健咨询业务的董事总经理兼副董事长；

Robert Langer

罗伯特·兰格

, professor at the David H. Koch Institute for Integrated Research at the

，大卫·H·科赫综合研究中心教授

Massachusetts Institute of Technology

麻省理工学院

;

；

Dennis Lee

丹尼斯·李

, senior program officer, accelerator at the Bill and Melinda Gates Foundation;

，高级项目官员，比尔及梅琳达·盖茨基金会加速器；

William McKeon

威廉·麦基恩

, president and CEO of the Texas Medical Center;

，德州医学中心的总裁兼首席执行官；

Ferran Prat

费兰·普拉特

, chief commercial officer at BostonGene;

波士顿基因公司的首席商务官；

Josh Richardson

约什·理查森

, managing director and senior investor on the life sciences investigating team at Goldman Sachs;

高盛生命科学调查团队的董事总经理兼资深投资人；

Robert Ruffolo

罗伯特·鲁福洛

, chairman of Aragen Biosciences;

，Aragen Biosciences董事长；

David Schull

大卫·舒尔

, president of Russo Partners;

，鲁索合伙公司的总裁；

Kevin Sheridan

凯文·谢里登

, managing director and joint global head of health care investment banking at Jefferies; and

Jefferies医疗保健投资银行的董事总经理兼全球联合主管；以及

Lisa Wright

丽莎·赖特

, president and CEO of Community Health Choice.

，社区健康选择的总裁兼首席执行官。

About the Rice Biotech Launch Pad:

关于水稻生物技术启动平台：

The Rice Biotech Launch Pad is a Houston-based accelerator focused on expediting the translation of Rice University's health and medical technology discoveries into cures. This initiative is designed to help advance internally discovered platform technologies from concept to clinical studies and commercialization.

莱斯生物技术发射台是一个位于休斯顿的加速器，专注于加快莱斯大学健康和医疗技术发现向治疗手段的转化。该计划旨在帮助内部发现的平台技术从概念推进到临床研究和商业化。

The Rice Biotech Launch Pad will identify and support highly differentiated projects while driving the expansion of Houston as a world-class medical innovation ecosystem. The accelerator will bring together local researchers with a network of industry executives. For more information, please visit .

莱斯生物技术发射台将识别和支持高度差异化的项目，同时推动休斯顿成为世界级的医疗创新生态系统。该加速器将把当地研究人员与行业高管网络聚集在一起。欲了解更多信息，请访问。

https://biotechlaunchpad.rice.edu/

。

Media Contacts:

媒体联系人：

Russo Partners

俄语合作伙伴

David Schull

大卫·舒尔

或

Liz Phillips

莉兹·菲利普斯